title: KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy.
abstract: Understanding the early evolution of cancer heterogeneity during the initial steps of tumorigenesis can uncover vulnerabilities of cancer cells that may be masked at later stages. We describe a comprehensive approach employing gene expression analysis in early lesions to identify novel therapeutic targets and the use of mouse models to test synthetic lethal drug combinations to treat human Kirsten rat sarcoma viral oncogene homologue (KRAS)-driven lung adenocarcinoma.
authors.affiliation: Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
authors.forename: Chiara
authors.initials: C
authors.lastname: Ambrogio
authors.affiliation: Department of Medical Oncology, Multidisciplinary Thoracic Oncology Unit , Catalan Institute of Oncology , Barcelona , Spain.
authors.forename: Ernest
authors.initials: E
authors.lastname: Nadal
authors.affiliation: Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, Barcelona, Spain; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
authors.forename: Alberto
authors.initials: A
authors.lastname: Villanueva
authors.affiliation: Bioinformatics Unit , Structural Biology and Biocomputing Programme, Centro Nacional de Investigaciones Oncológicas (CNIO) , Madrid , Spain.
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Gómez-López
authors.affiliation: Tumour Suppression, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO) , Madrid , Spain.
authors.forename: Timothy P
authors.initials: TP
authors.lastname: Cash
authors.affiliation: Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO) , Madrid , Spain.
authors.forename: Mariano
authors.initials: M
authors.lastname: Barbacid
authors.affiliation: Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO) , Madrid , Spain.
authors.forename: David
authors.initials: D
authors.lastname: Santamaría
keywords: KRAS; Lung adenocarcinoma